175 related articles for article (PubMed ID: 23945153)
1. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.
Casari C; Du V; Wu YP; Kauskot A; de Groot PG; Christophe OD; Denis CV; de Laat B; Lenting PJ
Blood; 2013 Oct; 122(16):2893-902. PubMed ID: 23945153
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
[TBL] [Abstract][Full Text] [Related]
3. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
[TBL] [Abstract][Full Text] [Related]
4. 2B or not 2B: when VWF is not a good platelet friend.
Castaman G
Blood; 2013 Oct; 122(16):2772-3. PubMed ID: 24136079
[No Abstract] [Full Text] [Related]
5. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
[TBL] [Abstract][Full Text] [Related]
6. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
Casonato A; Gallinaro L; Cattini MG; Pontara E; Padrini R; Bertomoro A; Daidone V; Pagnan A
Haematologica; 2010 Aug; 95(8):1366-72. PubMed ID: 20305138
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
[TBL] [Abstract][Full Text] [Related]
8. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
[TBL] [Abstract][Full Text] [Related]
9. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
[TBL] [Abstract][Full Text] [Related]
10. How I treat type 2B von Willebrand disease.
Kruse-Jarres R; Johnsen JM
Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
[TBL] [Abstract][Full Text] [Related]
11. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
[TBL] [Abstract][Full Text] [Related]
12. Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
Geys L; Roose E; Scroyen I; Rottensteiner H; Tersteeg C; Hoylaerts MF; Vanhoorelbeke K; Lijnen HR
J Thromb Haemost; 2018 Jan; 16(1):150-163. PubMed ID: 29121438
[TBL] [Abstract][Full Text] [Related]
13. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
[TBL] [Abstract][Full Text] [Related]
14. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.
Kauskot A; Poirault-Chassac S; Adam F; Muczynski V; Aymé G; Casari C; Bordet JC; Soukaseum C; Rothschild C; Proulle V; Pietrzyk-Nivau A; Berrou E; Christophe OD; Rosa JP; Lenting PJ; Bryckaert M; Denis CV; Baruch D
JCI Insight; 2016 Oct; 1(16):e88643. PubMed ID: 27734030
[TBL] [Abstract][Full Text] [Related]
15. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
16. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
Favaloro EJ
Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
[TBL] [Abstract][Full Text] [Related]
18. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.
Hamilton A; Ozelo M; Leggo J; Notley C; Brown H; Frontroth JP; Angelillo-Scherrer A; Baghaei F; Enayat SM; Favaloro E; Lillicrap D; Othman M
Thromb Haemost; 2011 Mar; 105(3):501-8. PubMed ID: 21301777
[TBL] [Abstract][Full Text] [Related]
19. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
Othman M
Semin Thromb Hemost; 2011 Jul; 37(5):464-9. PubMed ID: 22102188
[TBL] [Abstract][Full Text] [Related]
20. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
